UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number: 001-41661
Jin Medical International Ltd.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Press Release
On February 5, 2026, the Company published a press release entitled “Jin Medical CEO Fireside Chat”, a copy of which is attached hereto as Exhibit 99.1.
The information in the press release furnished in Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in the press release shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act of 1933, as amended, except in the event that the Company expressly states that such information is to be considered filed under the Exchange Act or incorporates it by specific reference in such filing.
1
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release dated February 5, 2026 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Jin Medical International Ltd. | ||
| Date: February 9, 2026 | By: | /s/ Erqi Wang |
| Erqi Wang | ||
| Chief Executive Officer | ||
3